menu search

Us equites - blackrock says there is too much optimism about corporate earnings

BlackRock Investment Institute with the cautionary heads up:“About half of expected earnings growth is tied to mega caps ... according to LSEG data,...

October 24, 2023, 12:28 am

Salesforce.com (crm) suffers a larger drop than the general market: key insights

In the closing of the recent trading day, Salesforce.com (CRM) stood at $202, denoting a -0.85% change ...

October 23, 2023, 6:47 pm

Why salesforce stock was falling on monday

Piper Sandler downgraded the stock today to a neutral rating. Analysts see the potential for weaker-than-expected revenue growth this year....

October 23, 2023, 12:36 pm

Ibm consulting and deluxe partner to optimize cash flow

IBM Consulting and payments and data company Deluxe joined forces to develop a receivables automation s...

October 23, 2023, 12:22 pm

Stagwell (stgw) chairman and ceo mark penn to present at 2023 ana masters of marketing conference

NEW YORK and ORLANDO, Fla. , Oct. 23, 2023 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today annou...

October 23, 2023, 12:14 pm

Opsmx announces industry’s first deployment firewall

New DevSecOps Capability Brings Active Policy Enforcement and Automated Compliance to Application Deliv...

October 23, 2023, 12:07 pm

Salesforce stock is falling. an analyst cites growth worries

Piper Sandler analyst Brent Bracelin turned cautious on cloud software stocks. But he still likes Microsoft stock....

October 23, 2023, 12:05 pm

Lockheed martin pulls out of us air force tanker competition

Lockheed Martin (NYSE:LMT) has pulled out from the United States Air force's competition to build at le...

October 23, 2023, 11:54 am

Enphase energy outshines the competition

The solar inverter market in the United States is a duopoly, with Enphase Energy and SolarEdge Technologies taking up almost all of the market share. ...

October 23, 2023, 11:21 am

Heads up: a note on the uk labour market data due tomorrow

In case you missed this headline last week: Heads up: UK labour market data today will only be a partial oneONS is now out with an operational note st...

October 23, 2023, 11:05 am

Exclusive: lockheed exits us air force tanker competition; lifting boeing's kc-46

Lockheed Martin Corp has withdrawn from the U.S. Air force's competition to build at least 75 refueling...

October 23, 2023, 9:52 am

Salesforce: ai expansion already well priced into valuation

Salesforce's shares surged by approximately 57% over the year, driven by a strong focus on AI integrati...

October 22, 2023, 9:29 pm

Ft reports that the eu is considering a gas price cap extension to avert winter crisis

The Financial Times is gated but the gist of the article is that the European Union is considering extending its emergency gas price cap introduced in...

October 22, 2023, 8:43 pm

Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...

October 22, 2023, 6:59 pm

Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...

October 22, 2023, 11:00 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am


Search within

Pages Search Results: